Panobinostat inhibits HDAC, which causes cell cycle arrest and apoptosis, and clinical trials have shown the use of Panobinostat in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma [62]. The gene discussed is HDAC9; the disease is AL amyloidosis.